Tag

Pbms

All articles tagged with #pbms

health-policy2 months ago•38 min saved

FTC Settlement Ushers in Net Pricing Drug Channel

The FTC’s landmark settlement with Express Scripts dismantles the PBM’s current incentives and launches a Net Pricing Drug Channel (NPDC): patient costs will be based on net price, rebates must be passed through to patients, formulary bias toward high-WAC drugs ends, direct-to-consumer pricing via TrumpRx is enabled, manufacturer fees must be delinked from list prices, and retailers will be reimbursed on a cost-plus basis. The Ascent Health Services GPO will move from Switzerland to the US, with a monitor and compliance reports and a deadline of January 1, 2028, signaling sweeping changes for plan sponsors, pharmacies, manufacturers, and PBM competitors.

via Drug Channels|

#express-scripts #health-policy #net-pricing-drug-channel

health1 year ago•10 min saved

Lawmakers Target Health Conglomerates and Drug Middlemen for Reform

The article discusses the role of pharmacy benefit managers (PBMs) in the rising costs of prescription drugs in the U.S., highlighting their consolidation with major insurance companies and the lack of transparency in their operations. Critics argue that PBMs inflate drug prices and limit access to affordable medications, contributing to a healthcare crisis where many Americans cannot afford necessary prescriptions. The Federal Trade Commission (FTC) has filed a lawsuit against major PBMs for anti-competitive practices, and bipartisan legislation has been introduced to break up their monopolistic control over the pharmacy supply chain.

via Truthout|

#drug-costs #ftc #health

healthcare2 years ago•4 min saved

Senate hearing on insulin prices unites lawmakers against pharma companies.

Insulin manufacturers and pharmacy benefit management (PBM) companies testified in front of the Senate Committee on Health, Education, Labor and Pensions (HELP) to address questions over the affordability of insulin. The drug manufacturing leaders cited numerous causes of insulin’s sky-high price that exist outside their companies, while PBM representatives blamed high list prices and a lack of competition in the market. The HELP committee is scheduled to meet again on Thursday for a markup session on several bills, including the Pharmacy Benefit Manager Reform Act, which would impose restrictions on how PBMs conduct their businesses.

via The Hill|

#drug-pricing #healthcare #insulin